DDInter173 DDInter1147
Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells. It is produced by recombinant DNA technology in a murine cell (NS0) expression system. Belimumab was first approved by the FDA on March 9, 2011, making it the newest drug to be approved for the treatment of SLE in more than 50 years. It is currently used to treat SLE and lupus nephritis.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Belimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Belimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Belimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dimethyl fumarate
Belimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Belimumab {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Belimumab {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Belimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Belimumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Belimumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Belimumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Belimumab may lead to a major life threatening interaction when taken with Tofacitinib
Belimumab may lead to a major life threatening interaction when taken with Natalizumab